Journal of Thrombosis and Thrombolysis

, Volume 30, Issue 4, pp 434–440 | Cite as

Mortality and morbidity following a major bleed in a registry population with acute ST elevation myocardial infarction

  • Shoaib AmlaniEmail author
  • Thanu Nadarajah
  • Rizwan Afzal
  • Renu Pal-Sayal
  • John W. Eikelboom
  • Madhu K. Natarajan


Major bleeding has been associated with an increased risk of ischemic events and death in patients with acute coronary syndromes. We examined the relationship between bleeding and outcome in 1,389 consecutive patients with ST-elevation myocardial infarction (STEMI) presenting to a tertiary center between May 1, 2003 and July 10, 2007. We recorded bleeding, length of stay and death during the first 30 days after hospitalization. Major bleeding occurred in 10.9% (152/1389, 95% confidence interval [CI] 9.3–12.6%). In hospital mortality was significantly higher in patients with major bleeding compared to those without major bleeding (19.7 vs. 8.2%, odds ratio [OR] 2.8, 95% CI 1.8–4.3) and was evident in the subgroups of patients with a low TIMI STEMI risk score (7.9 vs. 1.8%, OR 4.6, 95% CI 1.2–17.0) and medium risk score (11.7 vs. 6.3%, OR 2.0, 95% CI 0.6–6.2) but not those with a high TIMI STEMI risk score (28.8 vs. 26.1%, OR 1.2, 95% CI 0.7–2.0) (P for interaction = 0.024). Our data indicate that serious bleeding is common in patients with STEMI treated with thrombolysis or PCI and is a powerful predictor of death, particularly in patients with a low TIMI risk score. Therapies that maintain efficacy while reducing bleeding and that reduce the risk of death in patients who develop bleeding are needed.


Acute coronary syndrome ST elevation Bleeding Death Prognosis 


  1. 1.
    Eikelboom JW, Mehta SR, Anand SS, Xie C, Fox KA, Yusuf S (2006) Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circulation 114:774–782CrossRefPubMedGoogle Scholar
  2. 2.
    Rao SV, O’Grady K, Pieper KS, Granger CB, Newby LK, Van de Werf F, Mahaffey KW, Califf RM, Harrington RA (2005) Impact of bleeding severity on clinical outcomes among patients with acute coronary syndromes. Am J Cardiol 96:1200–1206CrossRefPubMedGoogle Scholar
  3. 3.
    Kinnaird TD, Stabile E, Mintz GS, Lee CW, Canos DA, Gevorkian N, Pinnow EE, Kent KM, Pichard AD, Satler LF, Weissman NJ, Lindsay J, Fuchs S (2003) Incidence, predictors, and prognostic implications of bleeding and blood transfusion following percutaneous coronary interventions. Am J Cardiol 92:930–935CrossRefPubMedGoogle Scholar
  4. 4.
    Manoukian SV, Feit F, Mehran R, Voeltz MD, Ebrahimi R, Hamon M, Dangas GD, Lincoff AM, White HD, Moses JW, King SB III, Ohman EM, Stone GW (2007) Impact of major bleeding on 30-day mortality and clinical outcomes in patients with acute coronary syndromes: an analysis from the ACUITY Trial. J Am Coll Cardiol 49:1362–1368CrossRefPubMedGoogle Scholar
  5. 5.
    Moscucci M, Fox KA, Cannon CP, Klein W, Lopez-Sendon J, Montalescot G, White K, Goldberg RJ (2003) Predictors of major bleeding in acute coronary syndromes: the Global Registry of Acute Coronary Events (GRACE). Eur Heart J 24:1815–1823CrossRefPubMedGoogle Scholar
  6. 6.
    Spencer FA, Moscucci M, Granger CB, Gore JM, Goldberg RJ, Steg PG, Goodman SG, Budaj A, FitzGerald G, Fox KAA (2007) Does comorbidity account for the excess mortality in patients with major bleeding in acute myocardial infarction? Circulation 116:2793–2801CrossRefPubMedGoogle Scholar
  7. 7.
    Berger PB, Manoukian SV (2007) Bleeding is bad…. isn’t it? Circulation 116:2776–2778CrossRefPubMedGoogle Scholar
  8. 8.
    Morrow DA, Antman EM, Charlesworth A, Cairns R, Murphy SA, de Lamos JA, Gugliano RP, McCabe CH, Braunwald E (2000) TIMI risk score for ST-elevation myocardial infarction: a convenient, bedside, clinical score for risk assessment at presentation; an intravenous nPA for treatment of infarcting myocardium early II trial substudy. Circulation 102:2031–2037PubMedGoogle Scholar
  9. 9.
    Menon V, Hochman JS (2002) Management of cardiogenic shock complicating acute myocardial infarction. Heart 88:531–537CrossRefPubMedGoogle Scholar
  10. 10.
    De Luca G, Suryapranata H, Ottervanger JP, Antman EM (2004) Time delay to treatment and mortality in primary angioplasty for acute myocardial infarction: every minute of delay counts. Circulation 109:1223–1225CrossRefPubMedGoogle Scholar
  11. 11.
    Kuch B, von Scheidt W, Kling B, Heier M, Hoermann A, Meisinger C (2008) Differential impact of admission C-reactive protein levels on 28-day mortality risk in patients with ST-elevation versus non-ST-elevation myocardial infarction (from the Monitoring Trends and Determinants on Cardiovascular Diseases [MONICA]/Cooperative Health Research in the Region of Augsburg [KORA] Augsburg Myocardial Infarction Registry). Am J Cardiol 102(9):1125–1130CrossRefPubMedGoogle Scholar
  12. 12.
    Giannitsis E, Müller-Bardorff M, Lehrke S, Wiegand U, Tölg R, Weidtmann B, Hartmann F, Richardt G, Katus HA (2001) Admission troponin T level predicts clinical outcomes, TIMI flow, and myocardial tissue perfusion after primary percutaneous intervention for acute ST-segment elevation myocardial infarction. Circulation 104:630–635CrossRefPubMedGoogle Scholar
  13. 13.
    Vis MM, Sjauw KD, van der Schaaf RJ, Koch KT, Baan J Jr, Tijssen JG, Piek JJ, de Winter RJ, Henriques JP (2007) Prognostic value of admission hemoglobin levels in ST-segment elevation myocardial infarction patients presenting with cardiogenic shock. Am J Cardiol 99:1201–1202CrossRefPubMedGoogle Scholar
  14. 14.
    Ottervanger JP, Misier ARR, Dambrink JH, de Boer MJ, Hoorntje JC, Gosselink AT, Suryapranata H, Reiffers S, van’t Hof AW (2007) Mortality in patients with left ventricular ejection fraction <30% after primary percutaneous coronary intervention for ST-elevation myocardial infarction. Am J Cardiol 100:793–797CrossRefPubMedGoogle Scholar
  15. 15.
    Gibson CM, Pinto DS, Murphy SA, Morrow DA, Hobbach HP, Wiviott SD, Giugliano RP, Cannon CP, Antman EM, Braunwald E, TIMI Study Group (2003) Association of creatinine and creatinine clearance on presentation in acute myocardial infarction with subsequent mortality. J Am Coll Cardiol 42:1535–1543CrossRefPubMedGoogle Scholar
  16. 16.
    Sobieraj-Teaguea M, Gallusa AS, Eikelboom JW (2008) The risk of iatrogenic bleeding in acute coronary syndromes and long-term mortality. Curr Opin Cardiol 23:327–334CrossRefGoogle Scholar
  17. 17.
    Lincoff AM, Bittl JA, Harrington RA, Feit F, Kleiman NS, Jackman JD, Sarembock IJ, Cohen DJ, Spriggs D, Ebrahimi R, Keren G, Carr J, Cohen EA, Betriu A, Desmet W, Kereiakes DJ, Rutsch W, Wilcox RG, de Feyter PJ, Vahanian A, Topol EJ, REPLACE-2 Investigators (2003) Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA 289:853–863CrossRefPubMedGoogle Scholar
  18. 18.
    Yusuf S, Mehta SR, Chrolavicius S, Afzal R, Pogue J, Granger CB, Budaj A, Peters RJ, Bassand JP, Wallentin L, Joyner C, Fox KA, Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators (2006) Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med 354:1464–1476CrossRefPubMedGoogle Scholar
  19. 19.
    Peters RJG, Joyner C, Bassand JP, Peters RJ, Joyner C, Bassand JP, Afzal R, Chrolavicius S, Mehta SR, Oldgren J, Wallentin L, Budaj A, Fox KA, Yusuf S, OASIS-6 Investigators (2008) The role of fondaparinux as an adjunct to thrombolytic therapy in acute myocardial infarction: a subgroup analysis of the OASIS-6 trial. Eur Heart J 29:324–331CrossRefPubMedGoogle Scholar
  20. 20.
    Stone GW, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, Kornowski R, Hartmann F, Gersh BJ, Pocock SJ, Dangas G, Wong SC, Kirtane AJ, Parise H, Mehran R, HORIZONS-AMI Trial Investigators (2008) Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med 358:2218–2230CrossRefPubMedGoogle Scholar
  21. 21.
    Agostoni P, Biondi-Zoccai GG, de Benedictis ML, Rigattieri S, Turri M, Anselmi M, Vassanelli C, Zardini P, Louvard Y, Hamon M (2004) Radial versus femoral approach for percutaneous coronary diagnostic and interventional procedures; Systematic overview and meta-analysis of randomized trials. J Am Coll Cardiol 44(2):349–356CrossRefPubMedGoogle Scholar
  22. 22.
    Jolly SS, Amlani S, Hamon M, Yusuf S, Mehta SR (2009) Radial versus femoral access for coronary angiography or intervention and the impact on major bleeding and ischemic events: a systematic review and meta-analysis of randomized trials. Am Heart J 157(1):132–140CrossRefPubMedGoogle Scholar
  23. 23.
    Mehta SR, Bassand JP, Chrolavicius S, Mehta SR, Bassand JP, Chrolavicius S, Diaz R, Fox KA, Granger CB, Jolly S, Rupprecht HJ, Widimsky P, Yusuf S, CURRENT-OASIS 7 Steering Committee (2008) Design and rationale of CURRENT-OASIS 7: a randomized, 2 × 2 factorial trial evaluating optimal dosing strategies for clopidogrel and aspirin in patients with ST and non-ST-elevation acute coronary syndromes managed with an early invasive strategy. Am Heart J 156(6):1080e1–1088e1CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  • Shoaib Amlani
    • 1
    Email author
  • Thanu Nadarajah
    • 1
  • Rizwan Afzal
    • 3
  • Renu Pal-Sayal
    • 3
  • John W. Eikelboom
    • 1
    • 2
    • 3
  • Madhu K. Natarajan
    • 1
    • 3
  1. 1.Department of MedicineMcMaster UniversityHamiltonCanada
  2. 2.Thrombosis Service, Hamilton Health Sciences—General DivisionHamiltonCanada
  3. 3.Population Health Research InstituteHamilton Health SciencesHamiltonCanada

Personalised recommendations